These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 26363301)

  • 1. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
    De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
    J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lyophilization and nebulization of pulmonary surfactant-coated nanogels for siRNA inhalation therapy.
    Merckx P; Lammens J; Nuytten G; Bogaert B; Guagliardo R; Maes T; Vervaet C; De Beer T; De Smedt SC; Raemdonck K
    Eur J Pharm Biopharm; 2020 Dec; 157():191-199. PubMed ID: 33022391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy.
    Merckx P; De Backer L; Van Hoecke L; Guagliardo R; Echaide M; Baatsen P; Olmeda B; Saelens X; Pérez-Gil J; De Smedt SC; Raemdonck K
    Acta Biomater; 2018 Sep; 78():236-246. PubMed ID: 30118853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonviral pulmonary delivery of siRNA.
    Merkel OM; Kissel T
    Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bio-inspired pulmonary surfactant-modified nanogels: A promising siRNA delivery system.
    De Backer L; Braeckmans K; Stuart MC; Demeester J; De Smedt SC; Raemdonck K
    J Control Release; 2015 May; 206():177-86. PubMed ID: 25791835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.
    Zhang Y; Almazi JG; Ong HX; Johansen MD; Ledger S; Traini D; Hansbro PM; Kelleher AD; Ahlenstiel CL
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy.
    Kim YD; Park TE; Singh B; Maharjan S; Choi YJ; Choung PH; Arote RB; Cho CS
    Nanomedicine (Lond); 2015; 10(7):1165-88. PubMed ID: 25929572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
    Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
    Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo.
    Lee SJ; Yook S; Yhee JY; Yoon HY; Kim MG; Ku SH; Kim SH; Park JH; Jeong JH; Kwon IC; Lee S; Lee H; Kim K
    J Control Release; 2015 Dec; 220(Pt B):631-41. PubMed ID: 26307351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in siRNA delivery.
    Sarisozen C; Salzano G; Torchilin VP
    Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
    Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
    Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy.
    Xu X; Wu J; Liu Y; Yu M; Zhao L; Zhu X; Bhasin S; Li Q; Ha E; Shi J; Farokhzad OC
    Angew Chem Int Ed Engl; 2016 Jun; 55(25):7091-7094. PubMed ID: 27140428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
    Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
    Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of natural pulmonary surfactant on the efficacy of siRNA-loaded dextran nanogels.
    De Backer L; Braeckmans K; Demeester J; De Smedt SC; Raemdonck K
    Nanomedicine (Lond); 2013 Oct; 8(10):1625-38. PubMed ID: 23418856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of siRNA Nanosheets for Efficient RNA Interference.
    Kim H; Lee JS; Lee JB
    Sci Rep; 2016 Apr; 6():25146. PubMed ID: 27120975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle-siRNA: A potential cancer therapy?
    Young SW; Stenzel M; Yang JL
    Crit Rev Oncol Hematol; 2016 Feb; 98():159-69. PubMed ID: 26597018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A RNA nanotechnology platform for a simultaneous two-in-one siRNA delivery and its application in synergistic RNAi therapy.
    Jang M; Han HD; Ahn HJ
    Sci Rep; 2016 Aug; 6():32363. PubMed ID: 27562435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unveiling the Molecular Structure of Pulmonary Surfactant Corona on Nanoparticles.
    Hu Q; Bai X; Hu G; Zuo YY
    ACS Nano; 2017 Jul; 11(7):6832-6842. PubMed ID: 28541666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary Delivery of siRNA via Polymeric Vectors as Therapies of Asthma.
    Xie Y; Merkel OM
    Arch Pharm (Weinheim); 2015 Oct; 348(10):681-8. PubMed ID: 26148454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.